Skip to main content
Log in

Transfection of normal primary human skeletal myoblasts with p21 and p57 antisense oligonucleotides to improve their proliferation: a first step towards an alternative molecular therapy approach of Duchenne muscular dystrophy

  • Original Article
  • Published:
Journal of Molecular Medicine Aims and scope Submit manuscript

Abstract

Duchenne muscular dystrophy (DMD), caused by the absence of dystrophin, is associated with decreased muscle cell proliferation. An increased p21 mRNA level in DMD patients may be involved in the process. In this context we are interested to improve the proliferation of primary human skeletal muscle cells (SkMC) by a reduction in the cell cycle proteins p21 and p57 using the appropriate antisense oligonucleotides (ASO). Therefore a transfection procedure needs to be optimized in which the oligonucleotide enters the SkMC with a minimal loss of cell vitality and high efficiency. Three different formulations, Effectene, DAC40, and SuperFect, were compared. Proliferation was analyzed comparing cells transfected with p21 and/or p57 ASO vs. cells transfected with scrambled ASO using a bromodeoxyuridine assay. Under optimal conditions (a mixture of 0.25 µg ASO, 5 µl Effectene, 0.8 µl enhancer) SkMC transfected with p21 ASO reveal an average increase in cell proliferation of 32.5±11% after 24 h. p57 ASO shows the same effect, but concomitant transfection of p21 and p57 does not enhance it. A cell vitality of 78±14% after 24 h was determined by the MTT test. SkMC transfected with DAC40 reveal a maximal increase in proliferation of 38±7% after 48 h and show a vitality of 65±8%. In contrast to both these formulations, SuperFect was found to be highly toxic for SkMC, with more than 70% dead cells after 24 h. The increase in proliferation, the functional biological effect of p21 ASO, is well correlated with a decrease in p21 detected by western blot analysis of 31.6% for Effectene. Transfection efficiency was measured directly by FACS analysis using FITC-labeled ASO and data showing ASO internalization in 75.8±11.2% of the cell population for Effectene and 74.4±6.6% cells for DAC40. Taken together transient transfection of p21 or p57 ASO into primary human SkMC using Effectene significantly improves their proliferation compared to transfection with scrambled ASO without a major loss of cell vitality. This represents a basis for the transfer of this technique to dystrophin-deficient SkMC cultures and the introduction of the short interference-RNA technique which might enhance the effect on cell proliferation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.

Similar content being viewed by others

Abbreviations

ASO :

Antisense oligonucleotides

BrdU :

5-Bromo-2′-deoxyuridine

DAC :

3β [N-(N, N′-Dimethylaminoethane)- carbamoyl] cholesterol

DMD :

Duchenne muscular dystrophy

FACS :

Fluorescence-activated cell sorter

FITC :

Fluorescein isothiocyanate

GAPDH :

Glyceraldehyde-3-phosphate dehydrogenase

MFI :

Mean fluorescence intensity

MTCC :

Muscle Tissue Culture Collection

MTT :

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

PS :

Protamine sulfate

SkMC :

Skeletal muscle cells

References

  1. Haslett JN, Sanoudou D, Kho AT, Bennett RR, Greenberg SA, Kohane IS, Beggs AH, Kunkel ML (2002) Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc Natl Acad Sci USA 99:15000–15005

    Article  CAS  PubMed  Google Scholar 

  2. Blau HM, Webster C, Pavlath GK (1983) Defective myoblasts identified in Duchenne muscular dystrophy. Proc Natl Acad Sci USA 80:4856–4860

    CAS  PubMed  Google Scholar 

  3. Skapek SX, Rhee J, Kim PS, Novitch BG, Lassar AB (1996) Cyclin-mediated inhibition of muscle gene expression via a mechanism that is independent of pRb hyperphosphorylation. Mol Cell Biol 16:7043–7053

    CAS  PubMed  Google Scholar 

  4. Zhang P, Wong C, Liu C, Finegold M, Harper JW, Elledge SJ (1999) p21CIP1 and p57KIP2 control muscle differentiation at the myogenin step. Genes Dev 13:213–224

    Article  CAS  PubMed  Google Scholar 

  5. Stein GH, Drullinger LF, Soulard A, Dulic V (1999) Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and diffenrentiation in human fibroblasts. Mol Cell Biol 19:2109–2117

    CAS  PubMed  Google Scholar 

  6. Endesfelder S, Krahn A, Kreuzer KA, Lass U, Schmidt CA, Jahrmarkt C, von Moers A, Speer A (2000) Elevated p21 mRNA level in skeletal muscle of DMD patients and mdx mice indicates either an exhausted satellite cell pool or a higher p21 expression in dystrophin-deficient cells. J Mol Med 78:569–574

    Article  CAS  PubMed  Google Scholar 

  7. Pritchard CC, Hsu L, Delrow J, Nelson PS (2001) Project normal: defining normal variance in mouse gene expression. Proc Natl Acad Sci USA 98:13266–13271

    Article  CAS  PubMed  Google Scholar 

  8. Campeau P, Chapdelaine P, Seigneurin-Venin S, Massie B, Tremblay JP (2001) Transfection of large plasmids in primary human myoblasts. Gene Ther 8:1387–1394

    Article  CAS  PubMed  Google Scholar 

  9. Armeanu S, Pelisek J, Krausz E, Fuchs A, Groth D, Curth R, Keil O, Quilici J, Rolland PH, Reszka R, Nikol S (2000) Optimization of nonviral gene transfer of vascular smooth muscle cells in vitro and in vivo. Mol Ther 1:366–375

    CAS  PubMed  Google Scholar 

  10. Pampinella F, Lechardeur D, Zanetti E, MacLachlan I, Benharouga M, Lukacs GL, Vitiello L (2002) Analysis of differential lipofection efficiency in primary and established myoblasts. Mol Ther 5:161–169

    Article  CAS  PubMed  Google Scholar 

  11. Ohtsubo M, Gamou S, Shimizu N (1998) Antisense oligonucleotide of WAF1 gene prevent EGF-induced cell-cycle arrest in A431 cells. Oncogene 16:797–802

    Article  CAS  PubMed  Google Scholar 

  12. Pedram A, Razandi M, Hu RM, Levin ER (1998) Astrocyte progression from G1 to S phase of the cell cycle depends upon multiple protein interaction. J Biol Chem 273:13966–13972

    Article  CAS  PubMed  Google Scholar 

  13. Mosmann T (1983) Rapid colometric assay for cellular growth and susvival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63

    CAS  PubMed  Google Scholar 

  14. Wittstock M, Rehfeldt C, Mix E, Zettl UK (2001) Comparison of three different proliferation assays for mouse myoblast cultures. Anal Biochem 292:166–169

    Article  CAS  PubMed  Google Scholar 

  15. Xiao X, Li J, Tsao YP, Dressman D, Hoffman EP, Watchko JF (2000) Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. J Virol 74:1436–1442

    Article  CAS  PubMed  Google Scholar 

  16. Wagner KR, Hamed S, Hadley DW, Gropman AL, Burstein AH, Escolar DM, Hoffman EP, Fischbeck KH (2001) Gentamicin treatment of Duchenne muscular dystrophy due to nonsense mutations. Ann Neurol 49:706–711

    Article  CAS  PubMed  Google Scholar 

  17. Bartlett RJ, Stockinger S, Denis MM, Bartlett WT, Inverardi L, Le TT, thi Man N, Morris GE, Bogan DJ, Metcalf-Bogan J, Kornegay JN (2000) In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide. Nat Biotechnol 18:615–622

    CAS  PubMed  Google Scholar 

  18. Rando TA, Disatnik MH, Zhou LZ (2000) Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides. Proc Natl Acad Sci USA 97:5363–5368

    CAS  PubMed  Google Scholar 

  19. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S, Morgan JE, Partridge TA, Wilton SD (2000) Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 98:42–47

    Article  Google Scholar 

  20. Heslop L, Beauchamp JR, Tajbakhsh S, Buckingham ME, Partridge TA, Zammit PS (2001) Transplanted primary neonatal myoblasts can give rise to functional satellite cells as identified using the Myf5nlacZI+ mouse. Gene Ther 8:778–783

    Article  CAS  PubMed  Google Scholar 

  21. Escolar DM, Henricson EK, Mayhew J, Florence J, Leshner R, Patel KM, Clemens PR (2001) Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children. Muscle Nerve 24:787–793

    Article  CAS  PubMed  Google Scholar 

  22. Burton WA, Tinsley JM, Holzfeind PJ, Rodrigues NR, Davies KE (1999) A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy. Proc Natl Acad Sci USA 96:14025–14030

    Article  CAS  PubMed  Google Scholar 

  23. Park CW, Chung JH (2001) Age-dependent change of p57Kip2 and p21Cip1/WafI expression in skeletal muscle and lung of mice. Biochim Biophys Acta 1520:163–168

    Article  CAS  PubMed  Google Scholar 

  24. Bergeron D, Barbeau B, Leger C, Rassart E (1995) Experimental bias in the evaluation of the cellular transient expression in DNA co-transfection experiments. Cell Mol Biol Res 41:155–159

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The support of Jana Richter, Bärbel Pohl, and Gudrun Hartmann are gratefully acknowledged. Human myoblast cultures were obtained from the Muscle Tissue Culture Collection (MTCC) at the Friedrich Baur Institute. The MTCC is part of the German network on muscular dystrophies funded by the German Ministry of Education and Research. The MTCC is also a partner of Eurobiobank funded by the EC. This research was supported by the Deutsche Gesellschaft für Muskelkranke and BMBF/AiF grant (1703402). S.E. is a fellow of the Berliner Programm zur Förderung der Chancengleichheit für Frauen in Forschung und Lehre.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Astrid Speer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Endesfelder, S., Bucher, S., Kliche, A. et al. Transfection of normal primary human skeletal myoblasts with p21 and p57 antisense oligonucleotides to improve their proliferation: a first step towards an alternative molecular therapy approach of Duchenne muscular dystrophy. J Mol Med 81, 355–362 (2003). https://doi.org/10.1007/s00109-003-0439-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00109-003-0439-6

Keywords

Navigation